
Earlier this year, the Lundbeck Foundation merged its two investment arms Emerge and Ventures together to form Biocapital, which focuses exclusively on early-stage life science startups.
The foundation is now strengthening the team through the hire of Kevin Dalgaard as principal. He comes to the role from a position as strategic partner of business development at Boehringer Ingelheim, where he was also responsible for the German firm’s global licensing activities within cardiovascular disease, metabolic disorders and eye diseases.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app